Regulus filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC, which includes, among other things, the recommendation of Regulus’s board of directors that Regulus’s stockholders ...

The mental health and wellbeing of our people is vitally important. It is a natural extension of our company’s purpose to discover new ways to improve and extend people’s lives. Our ambition at ...

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...

At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the ...

To report an adverse event or any drug related issues concerning Novartis medicinal products; please contact Novartis Patient Safety: Tel: +202 22861000 - Press 3 for reporting an adverse event.

Novartis is proud to share that CEO Vas Narasimhan, M.D., has been named to the 2025 TIME100 Health list—recognizing 100 of the most influential people driving the future of global health. Selected by ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Fabhalta APPULSE-PNH full results build on Phase III program, reporting new data from expanded PNH population in adults switching from anti-C5 Ianalumab Phase II data in immune thrombocytopenia and ...

Syftet med studien är att utvärdera effekt och säkerhet av remibrutinib (LOU064) när det ges till patienter med skovvis förlöpande multipel skleros. Studiens huvudsyfte är att ta reda på om patienter ...

2025年4月29日、スイス・バーゼル発 ― ノバルティスCEOのヴァス･ナラシンハンは、2025年第1四半期の業績について、次のようにコメントしています。 「ノバルティスは、2025年第1四半期の ...